Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 10

recruiting
3 968
countries
28
conditions
2 103

211 trials match your criteria

Plasma cell myeloma

Not recruiting

Study Comparing Belantamab Mafodotin with Lenalidomide and Dexamethasone to Daratumumab with Lenalidomide and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Belantamab Mafodotin

Radius fracture

Not recruiting

Study on Post-Surgery Pain Relief for Radius Fracture Patients Using Ropivacaine and Oxycodone

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone

Primary amyloidosis

Not recruiting

Study on the Safety and Effectiveness of Sargramostim with Daratumumab, Cyclophosphamide, Bortezomib, and Dexamethasone in Untreated Light Chain Amyloidosis Patients

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib

Plasma cell myeloma

Not recruiting

Study Comparing Lenalidomide, Carfilzomib, and Dexamethasone with Lenalidomide, Bortezomib, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib

Plasma cell myeloma

Not recruiting

Study of belantamab mafodotin with drug combination for newly diagnosed multiple myeloma patients who cannot receive transplant

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Belantamab Mafodotin

Plasma cell myeloma

Not recruiting

Study of belantamab mafodotin combined with pomalidomide, dexamethasone, and daratumumab in patients with relapsed/refractory multiple myeloma who previously had 1-3 treatments and are lenalidomide resistant

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Belantamab Mafodotin

Plasma cell myeloma

Not recruiting

Study of Isatuximab with drug combination for newly diagnosed multiple myeloma patients with severe kidney problems

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib

Plasma cell myeloma

Not recruiting

Study on the Safety and Effects of Belantamab Mafodotin with Lenalidomide and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Belantamab Mafodotin

Plasma cell myeloma

Not recruiting

Study Comparing Lenalidomide, Daratumumab, and Dexamethasone for Frail Patients with Untreated Multiple Myeloma Not Eligible for High-Dose Therapy

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:65+ years
  • Substances:Daratumumab

Hormone-refractory prostate cancer+1

Not recruiting

Study of PF-06821497 with Enzalutamide for Men with Metastatic Castration-Resistant Prostate Cancer Previously Treated with Abiraterone Acetate

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone

Plasma cell myeloma refractory

Not recruiting

Study Comparing Anitocabtagene Autoleucel with Standard Treatment for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib

Plasma cell myeloma refractory

Not recruiting

Study on Iberdomide, Cyclophosphamide, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.